 Biocept Inc NASDAQ:BIOC FRA:B003 said it has received a positive final Local Coverage Determination LCD from the Centers for Medicare Medicaid Services CMS Molecular Diagnostics Program MolDx, which will expand Medicare coverage for use of Biocepts Target Selector assay to identify the HER2 biomarker from circulating tumor cells CTCs. The company said the reimbursement decision expands access to testing that provides critical information used to guide targeted treatment options for patients with breast cancer. 